TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04004819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: A lower dosage of rituximab for HTLV-1-associated myelopathy
Study: NCT01296191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: One drop 4 times daily for 3 days and one drop the day of sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: besifloxacin
Description: One drop 4 times daily for 3 days and one drop on day of sample collection
Study: NCT03844269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKL-T01
Description: AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level.
Study: NCT03823196

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum900
Description: Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum1800
Description: Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
Study: NCT00413257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: néfopam
Description: bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: bolus NaCl during 10 min at the end of surgery and during postoperative H48
Study: NCT04370418

Intervention type: DRUG
Group type: OTHER
Intervention: short course chemo-radiation with 5-fluorouracil
Description: neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
Study: NCT03495713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
Study: NCT03663504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Preparation
Description: No preparation before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin and Flagyl
Description: Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
Study: NCT03737240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec (U-100)
Description: Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
Study: NCT02700191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uCor
Study: NCT03873337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persistence Targeted Smoking Cessation in SMI (PTSC-S)
Description: All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: All participants will receive 10 weeks of nicotine patch
Study: NCT00073814

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI QID
Study: NCT03304470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 2% Cream
Description: Anhydrous Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 Cream Vehicle
Description: Anhydrous Cream
Study: NCT00995670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
Study: NCT04697433

Intervention type: DEVICE
Intervention: Myotonometry
Description: The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
Study: NCT00293423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: 25 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: 25 mcg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgical Resection
Description: Patients will undergo standard surgical resection of intracranial tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgical Resection
Description: Patients will undergo standard surgical resection of intracranial tumor
Study: NCT03691753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitaya Vena Cava Filter System
Description: After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aegisy Vena Cava Filter
Description: After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
Study: NCT03658993

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Oral Rifaximin 550 mg TID for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Oral Rifaximin 550 mg TID for 4 weeks.
Study: NCT00835107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone hydrochloride
Description: oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator, oral capsules, BID, for one month
Study: NCT04015414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine
Description: 185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
Study: NCT03472274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg every 4 weeks x 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg every 4 weeks x 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-based neoadjuvant chemotherapy
Description: Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1
Study: NCT02089620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: will be used every 21 days for three months by the patient

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calver
Description: Calver will be given daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Patients will receive a daily placebo similar in size and structure to calvar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1
Description: Patients will receive a daily placebo similar in size and structure to calvar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
Study: NCT04158986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-driven post-discharge intervention
Description: Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~* Filling in the Chronic Liver Disease Questionnaire.~* Therapeutic conversations including drawing and review of genogram and eco-map.~* Information about- and help to initiate contact to relevant municipal offers.~* Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge
Study: NCT04597619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Nonopioid Pathway
Description: The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
Study: NCT03448861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polso Wearebale watch
Description: The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
Study: NCT03110419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
Study: NCT02947022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium DTPA
Description: On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc DTPA
Description: On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart.
Study: NCT01574144

Intervention type: DEVICE
Intervention: AVIVO™ PiiX Patch Monitor System
Description: External monitoring for 30 days post-discharge.
Study: NCT03204435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microsurgical aneurysmal operating techniques
Description: The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microsurgical aneurysmal operating techniques
Description: The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular techniques for cerebrovascular stenosis
Description: The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endovascular techniques for cerebrovascular stenosis
Description: The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
Study: NCT03678558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytochalasin B supplemented vitrification medium
Description: Vitrification of human oocyte in medium supplemented with Cytochalasin B
Study: NCT01238744

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed drink
Description: Drink containing flaxseed mucilage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed drink
Description: Drink containing flaxseed mucilage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed tablet
Description: Tablets containing flaxseed mucilage consumed with a control drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: Control drink
Study: NCT01061151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine (ZDV)
Description: 300 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine (NVP): Antepartum Mothers
Description: 200 mg at onset of labor
Study: NCT03204435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular techniques for intracranial aneurysms
Description: The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endovascular techniques for intracranial aneurysms
Description: The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid endarterectomy
Description: A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: carotid endarterectomy
Description: A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
Study: NCT00469638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial catheter ablation guided by introducer using Agilis sheeth
Description: Left atrial catheter ablation guided by introducer using Agilis sheeth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial catheter ablation guided by introducer using Non-steerable sheeth
Description: Left atrial catheter ablation guided by introducer using Non-steerable sheeth
Study: NCT01770691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPI vaginal pessary
Description: TIPI vaginal pessary G3 model, and TIPI SMD's
Study: NCT01935336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45mg taken by mouth each day at the same time with or without food
Study: NCT00050986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Starting Dose Level: 100 mg/m\^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
Study: NCT01061151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail
Description: 200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine-Zidovudine (3TC-ZDV)
Description: 150 mg/300 mg twice daily
Study: NCT00050986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R115777
Description: Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
Study: NCT02178293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzidamine hydrochloride
Study: NCT01061151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV-RTV)
Description: 400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
Study: NCT02178293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt
Study: NCT04259138

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Treatment Algorithm C
Description: Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.
Study: NCT01061151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV-RTV)
Description: 400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV-RTV)
Description: 400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])
Description: 200 mg/300 mg